Prepulse Inhibition of Startle in Cocaine Dependence - 7

NCT ID: NCT00015249

Last Updated: 2017-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

1997-02-28

Study Completion Date

1998-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine-Related Disorders Substance-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amantadine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cocaine dependence. Male. Right handed. Negative urine for cocaine

Exclusion Criteria

Positive urine for cocaine. History of head trauma. Significant medical disease.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New York MDRU

OTHER

Sponsor Role collaborator

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Rotrosen, M.D.

Role: PRINCIPAL_INVESTIGATOR

New York MDRU

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York MDRU

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

CPDD, 98, 99 NIDA Research Monograph Series 179, 1998 Manuscript submitted..

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Y01-5-0013-7

Identifier Type: -

Identifier Source: secondary_id

NIDA-5-0013-7

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cocaine Use Disorder and Cortical Dopamine
NCT03349606 COMPLETED EARLY_PHASE1
Impulsivity and Stimulant Administration
NCT01978431 COMPLETED PHASE1
Stress Hormones and Human Cocaine Use - 7
NCT00000290 COMPLETED PHASE1
Phendimetrazine and Cocaine
NCT02233647 COMPLETED EARLY_PHASE1
Brain Mechanisms in Young Adults
NCT03606473 COMPLETED EARLY_PHASE1